PL BioScience Secures Exclusive Japanese Distribution Deal with Summit Pharmaceuticals

PL BioScience GmbH has entered an exclusive distribution agreement with Summit Pharmaceuticals International (SPI) for the Japanese market. This marks PL BioScience's inaugural distribution collaboration in Japan, set to boost local access to its Human Platelet Lysate products, specifically the ELAREM™ Ultimate-FD PLUS (GMP Grade).

The Japanese cell culture media market is anticipated to grow annually by 12–14% over the next decade, driven by advancements in research, biopharmaceuticals, and regenerative medicine. SPI, a subsidiary of Sumitomo Corporation, will handle product supply, commercial support, and procurement streamlining for PL BioScience in Japan.

SPI connects global pharmaceutical firms and provides extensive services including bioresources, licensing, and manufacturing support. This partnership aims to fortify PL BioScience's presence and enhance product adoption within Japan's burgeoning market.